News
No benefit from lower temps for out-of-hospital cardiac arrest
October 20, 2021
The results “do not support the use of moderate therapeutic hypothermia to improve neurologic outcomes in comatose survivors of out-of-hospital cardiac arrest.”
News
Some diabetes drugs may lower risk of severe COVID-19 outcomes
October 19, 2021
Glucose-regulating medications may improve outcomes in COVID-19 patients with type 2 diabetes, a multinational retrospective cohort study suggests.
News
Omega-3s tame inflammation in elderly COVID-19 patients
October 13, 2021
Those who received an intravenous infusion had significant decreases from baseline to end of treatment in the neutrophil-to-lymphocyte ratio.
News
Rivaroxaban’s single daily dose may lead to higher bleeding risk than other DOACs
October 11, 2021
Corroborating previous studies, Iceland researchers report that rivaroxaban poses the highest risk of GI bleeding, compared with other DOACs.
![1]()
News
New reports help nail down myocarditis risk with COVID-19 vaccine
October 11, 2021
Myocarditis linked to the two mRNA SARS-CoV-2 vaccines is rare, usually mild and self-limited, and a lot less likely than the usually more severe cases seen in COVID-19.
News
Is AFib a stroke cause or innocent bystander? The debate continues
October 5, 2021
Many believe AFib is a risk marker for stroke, but new evidence suggests it may be a causal risk factor.
![1]()
News
Heart failure hospitalization risk lower with SGLT2 inhibitors than GLP-1 RAs
September 27, 2021
SGLT2 inhibitor versus GLP-1 RA use was associated with a significantly lower rate of hospitalization for heart failure in people with diabetes.
News
Cardiogenic shock teams again tied to lower mortality
September 23, 2021
New data suggest centers with a shock team had higher survival and lower resource use in the cardiac ICU.
![1]()
News
Refined heart rate cutoffs may improve prognostic value of acute PE scoring systems
September 21, 2021
In an observational registry-based study, dropping the 110-bpm heart rate threshold improved sensitivity for low-risk PE, while increasing it improved specificity for intermediate-high–risk PE.
![1]()
News
EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition
September 20, 2021
Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say forget that.
